CRISPR Therapeutics CTX213 (CTX211 programme successor)
CRISPR Therapeutics (originated via ViaCyte; licensed to Vertex Pharmaceuticals 2023–2024)
A preclinical successor with limited predecessor human evidence.
What it is
CTX213 is a preclinical, device-free gene-edited islet candidate. Its predecessor CTX211 reached five trial participants, with limited company-reported findings; that earlier human experience does not establish CTX213 efficacy, safety or durability.
Editorial review: .
Most recent recorded citation dates: 2026-08-03; 2026-08-03. Some dates overlap at their stated precision or share the same date. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Preclinical evidence. Benefit in people has not been established.See the linked studies and their populations →
- Benefit or performance
- Efficacy: The company reports CTX213 preclinical activity, not human efficacy. CTX211 C-peptide observations concern the earlier device-containing product.[6]
- Important harms and treatment burden
- Safety: CTX213 has no reported clinical safety results. The retrievable CTX211 device is absent from the successor, so its removability is not a CTX213 safety feature.[6]
- Approval and country access
- No current CTX213 treatment access or clinical eligibility is established. The terminated CTX211 trial is historical context, not an open study for the successor.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Durability: Human durability has not been demonstrated for CTX213. Earlier CTX211 follow-up cannot establish survival of a different, device-free product.[7]
Research status alone does not establish approval, clinical benefit or local availability. This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. This speculative assessment includes intended performance or preclinical findings; it does not establish benefit in people.
Default calculation: 15 × 20 + 10 × 12 + 20 × 16 + 20 × 12 + 35 × 20 + 12 × 20 = 1920; divide by total weight 100. Unrounded weighted result: 19.2.
The company reports CTX213 preclinical activity, not human efficacy. CTX211 C-peptide observations concern the earlier device-containing product.[6]
Human durability has not been demonstrated for CTX213. Earlier CTX211 follow-up cannot establish survival of a different, device-free product.[7]
CTX213 has no reported clinical safety results. The retrievable CTX211 device is absent from the successor, so its removability is not a CTX213 safety feature.[6]
No current CTX213 clinical eligibility is established. The predecessor trial’s ages and immunosuppression exclusions are not a successor-product label.[6]
Hypoimmune editing is intended to reduce immune rejection, but CTX213 has not demonstrated drug-free graft survival in humans.[7]
The August update describes CTX213 as progressing toward the clinic; the current candidate remains preclinical.[6]
Immunosuppression-free is scored here, as it is for cell replacement and encapsulation — freeing a therapy from lifelong anti-rejection drugs is the central barrier this whole pillar is trying to clear, so an approach that achieves it must be able to earn credit for it. It is scored on evidence, not intent: a platform designed to avoid immunosuppression but never yet tested at a therapeutic dose scores on what it has shown. Approaches that transplant nothing (in-vivo gene therapy, reprogramming) need no anti-rejection drugs by construction, but they still face the original autoimmune attack — that unresolved risk belongs in this score, not hidden by it.
The full picture
Current candidate and scoring scope
CTX213 is the current candidate being scored. It is a device-free precursor-islet product derived from gene-edited induced pluripotent stem cells. The August 2026 company update describes preclinical activity and development toward the clinic. No CTX213 human study was found in the 16 September ClinicalTrials.gov name search.1 2
What the predecessor contributes
The earlier VCTX211/CTX211 product used an implanted device. Its registry records five enrolled participants and a terminated trial, with no posted results. The protocol excluded chronic immunosuppression, but an exclusion criterion is not a report of every recipient's complete treatment course.3
The company's 3 August 2026 presentation, slide 41, reports that CTX211 was tolerated without serious adverse events or adverse events of special interest, that C-peptide persisted at 12 months, and that histology showed transplanted insulin-producing cells despite device fibrosis and immune-cell infiltration. These are company-reported predecessor findings. They are more detailed than the earlier press-release sentence, but remain without a full public clinical results dataset.4
The same slide presents CTX213 results in a chemically induced diabetic rat model. Animal findings are not human insulin independence, and do not establish control of human autoimmune T1D.4
Why these cannot be combined into one clinical claim
CTX213 changes the cell product and delivery approach. The predecessor's human exposure does not establish successor efficacy, safety, durability or immunosuppression requirements. In particular, removal of an implanted CTX211 device is not a safety feature of device-free CTX213. Future clinical eligibility and access are also unknown; the historical trial's adult age limits are not CTX213 eligibility.
The human programme history remains relevant context. The current evidence badge and editorial criteria reflect the preclinical successor, not a pooled assessment of two different products.
Coming soon
ETA · CTX213 remains preclinical in the August 2026 company update; no human study was found in the 16 September ClinicalTrials.gov name search. A clinical start and availability date are unconfirmed.
- →A registered first-in-human CTX213 study · Not established in the sources checked
- →Full CTX211 clinical results beyond company slides · Not established
Sources
- [1]CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones · Manufacturer · 2026-01-12 — Verbatim (verified 2026-07-15) "Clinical data generated from CTX211 were promising, demonstrating detectable C-peptide levels 12 months after implantation." / "These data have informed the Company's approach to hypoimmune cell engineering, supporting a transition to a next-generation candidate, CTX213." / "CTX213 has demonstrated compelling preclinical efficacy and is progressing towards the clinic." Company claim — no numbers, no peer review.
- [2]CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results · Manufacturer · 2026-05-04 — Verbatim (verified 2026-07-15) CTX213 is "a deviceless beta cell replacement candidate for Type 1 diabetes, consisting of unencapsulated precursor islet cells derived from edited induced pluripotent stem cells (iPSCs)" and "has demonstrated compelling preclinical efficacy through direct administration and is progressing toward the clinic." Preclinical, by the company's own word.
- [3]CRISPR Therapeutics pipeline — CTX213 (Regenerative Medicine) · Manufacturer — Accessed 2026-07-15. CTX213 is listed as an "unencapsulated investigational allogeneic, gene-edited, immune-evasive, stem cell-derived beta-cell replacement therapy" for type 1 diabetes, wholly owned, and is not marked as clinical-stage. CTX211 no longer appears on the pipeline.
- [4]VCTX211 first-in-human study: terminated, five enrolled, no posted results · Trial registry — Current registry retrieved 16 September 2026. Exclusion of chronic immunosuppression is a protocol criterion, not documentation of every participant’s full treatment course.
- [5]ClinicalTrials.gov query for CTX213 — no studies returned · Trial registry — Name search repeated 16 September 2026: zero studies. This does not exclude differently named or non-US registrations.
- [6]CRISPR Therapeutics Q2 2026 update — CTX213 preclinical development · Manufacturer · 2026-08-03
- [7]CRISPR Therapeutics corporate update, 3 August 2026 — CTX211 and CTX213, slide 41 · Manufacturer · 2026-08-03 — Company presentation reports predecessor CTX211 safety and histology; these are not CTX213 human results or a peer-reviewed clinical dataset.